Previous
Equity Source announces OrthoMediTec conducted its first WaisFix100 clinical trial
Added: (Mon Jan 07 2008)
OrthoMediTec, an Equity Source portfolio company conducted its first WaisFix100 clinical trial. WaisFix100 is a groundbreaking solution for the treatment of proximal femoral fracture, a major market within trauma care. Current fixation failure rates for femoral fractures are high using current surgical methods; fractures have average failure rates of up to 45%. WaisFix100 is the first commercially available device that reduces morbidity and mortality by increasing recovery rates and reducing blood loss and damage to tissue. The WaisFix100 fixation device is designed to provide benefits such as minimally invasive accelerated fixation and early weight-bearing.
OrthoMediTec is a medical device company established in 2005, providing surgeons with innovative, minimally invasive devices for the treatment of patients in orthopaedic trauma care. The chief scientist of OrthoMediTec has been widely published in leading orthopaedic journals including the Journal of Trauma. OrthoMediTec has been approved in the end of 2007 for clinical trials in humans by the Israeli Helsinki Committee and the companys chief scientist conducted its first WaisFix100 clinical trial at the Carmel Medical Centre.
Equity Source reports that the number of global hip fractures (occidental world) performed on a yearly basis has been estimated at 1,080,000-1,500,000 per annum, with the total yearly trauma products market size is estimated at $856 million, with an annual growth of approximately 7%.
With its head office in the United Kingdom, Equity Source is the only independent corporate technology firm focused on identifying valuable developments and facilitating new strategic partnerships.
(www.equitysource.co.uk)
(www.orthomeditec.com)